PALO ALTO, Calif., Oct. 6, 2014 /PRNewswire/ -- The latest interim data from XPAND, AirXpanders Inc.'s U.S.-based, head-to-head pivotal study of its new, needle-free, patient-controlled tissue expansion system for mastectomy patients undergoing breast reconstruction, will be presented at Plastic Surgery 2014, the annual meeting of the American Society of Plastic Surgeons (ASPS). In addition, the results of several separate analyses and studies investigating the impact of air travel and radiation therapy on patients with the AeroForm expanders implanted will also be presented. The conference is taking place in Chicago from October 10 to 14.
For product demonstrations of the investigational AeroForm device, please visit AirXpanders at booth 626 at the conference.
Below are details about key AeroForm-related presentations at the meeting:
Title: | The Future of Tissue Expansion For Two Stage Breast Reconstruction Procedures |
Presenter: | Dr. Anthony Connell The Mount Hospital, Perth Australia |
Session Type: | Hot Topics for Residents: 11:05 a.m. 12:30 p.m. Room W184a-d |
Date/Time: | Friday, October 10, 2014. |
Title: | XPAND Patient Activated Controlled Tissue Expansion System: A U.S, Multi-centered, Randomized Controlled Trial |
Presenter: | Dr. Jeffrey Ascherman Columbia Presbyterian Medical Center |
Session Type: | Scientific Paper Session: Breast 2 1:15 p.m. 2:30 p.m. Room W196B |
Date/Time: | Sunday, October 12, 2014 |
Title: | The Use of Radiotherapy and Altitude Effects on the AeroForm Tissue Expander |
Presenter: | Dr. Anthony Connell The Mount Hospital, Perth Australia |
Session Type: | Scientific Paper Session: Breast 2 1:15 p.m. 2:30 p.m. Room W196B |
Date/Time: | Sunday, October 12, 2014 |
About AirXpanders
AirXpanders Inc. (www.airxpanders.com) is a tissue-expansion company focused on the area of breast cancer reconstruction. By employing a revolutionary patient-controlled expander, activated by a wireless remote control, the often painful process of recovering one's feminine shape after cancer can potentially be eased with this needle-free technology that is easy to use and may enable the patient to proceed to a permanent implant much faster than the current standard-of-care. At this time, AirXpanders' products are not cleared or approved for sale. AirXpanders is backed by Vivo Ventures, GBS Venture Partners, Prolog Ventures, Heron Capital and Shalon Ventures.
Media Contact:
Erich Sandoval
Lazar Partners LTD.
Tel. 917-497-2867
E-mail: esandoval@lazarpartners.com
SOURCE AirXpanders Inc.
